Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.In a randomized clinica...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Tulika Ranjan, Soma Sengupta, Michael Glantz, Richard M. Green, Alexander Yu, Dawit Aregawi, Rekha Chaudhary, Ricky Chen, Mario Zuccarello, Christine Lu‐Emerson, Hugh D. Moulding, Neil D. Belman, Jon Glass, Aaron Mammoser, Mark D. Anderson, Jagan Valluri, Nicholas F. Marko, Jason Schroeder, Steven J. Jubelirer, Frances Chow, Pier Paolo Claudio, Anthony Alberico, Seth T. Lirette, Krista L. Denning, Candace M. Howard
स्वरूप: Artigo
भाषा:अंग्रेज़ी
प्रकाशित: 2023
ऑनलाइन पहुंच:https://doi.org/10.1016/j.xcrm.2023.101025
https://www.cell.com/article/S2666379123001350/pdf
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

इंटरनेट

https://doi.org/10.1016/j.xcrm.2023.101025
https://www.cell.com/article/S2666379123001350/pdf

समान संसाधन